What is the 13F Pro Quality Score for HRMY?

13F Pro ranks Harmony Biosciences Holdings, Inc. (HRMY) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View HRMY's current score at https://13fpro.ai/company/HRMY (free sign-up required for the full ranking).

Which hedge funds own the most HRMY stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of HRMY include BlackRock,, FMR, VANGUARD PORTFOLIO MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/HRMY as soon as new 13F filings post.

Where does 13F Pro source HRMY data?

All Harmony Biosciences Holdings, Inc. fundamentals and ownership data come directly from SEC EDGAR. Harmony Biosciences Holdings, Inc. files with the SEC under CIK 1802665. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is HRMY in?

Harmony Biosciences Holdings, Inc. (HRMY) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives HRMY's revenue?

Per Harmony Biosciences Holdings, Inc.'s latest 10-Q filed with the SEC on 2026-08-04, the biggest revenue drivers are: Rare neurological diseases (WAKIX net product revenue) ($261.3M, +30.3% YoY); Units shipped; Price. Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/HRMY.

What are HRMY's largest expenses?

Harmony Biosciences Holdings, Inc.'s latest 10-Q reports these as the largest expense items: Cost of product sold ($63.2M, +65.6% YoY); Research and development ($46.6M, -7.1% YoY); Sales and marketing ($34.1M, +13.5% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is HRMY research updated on 13F Pro?

HRMY's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Harmony Biosciences Holdings, Inc.(HRMY)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 1802665 HRMY stock profile & AI dashboard →

13F Pro Quality Score

71.4/100

Rank #185 of 2,960 stocksTOP 10%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

83.9/100

Profitability

72.0/100

Balance Sheet

92.6/100

Earnings Quality

83.1/100

Free Cash Flow

89.4/100

Institutional Flow

10.7/100

Revenue Scale

49.2/100

Dilution Risk

24.4/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why HRMY Scores 71/100

exact factor attribution · 2026-09-12

HRMY's composite is driven by revenue growth and free cash flow, held back by institutional flow and shareholder dilution. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+6.8 pts

84th pct

Free cash flow

+5.9 pts

89th pct

Capital efficiency

+4.3 pts

93th pct

Earnings quality

+3.3 pts

83th pct

Profitability

+3.3 pts

72th pct

Earnings growth

+1.2 pts

74th pct

Scale

-0.1 pts

49th pct

Shareholder dilution

-1.3 pts

24th pct

Institutional flow

-2.0 pts

11th pct

Latest change (2026-08-04): 75 → 72 · ↓ Revenue growth 82→67

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

HRMY Stock Analysis & AI Quality Score

Data updated 2026-09-12

AI stock analysis and institutional research for Harmony Biosciences Holdings, Inc. (HRMY), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores HRMY at 71.4/100 on a 32-signal composite quality model, placing it at rank #185 of 2,960 stocks — the top 10% of the AI-ranked universe. HRMY scores in the top quartile across balance sheet strength (92.6), free cash flow (89.4), revenue growth (83.9). Areas of concern include institutional flow (10.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 24.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Harmony Biosciences Holdings, Inc. reports quarterly revenue of $261.3M, net income of $75.4M. Top institutional holders of HRMY by reported 13-F value include BlackRock, FMR, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. HRMY trades on the Nasdaq exchange and files with the SEC under CIK 1802665. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate HRMY daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Harmony Biosciences Holdings, Inc. directly from SEC EDGAR. Harmony Biosciences Holdings, Inc.'s 13F Pro composite quality score has ranged between 41 and 83 since 2021, currently 71.4 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about Harmony Biosciences Holdings, Inc.

Quirks, history, and lore behind HRMY — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. specialty pharmaceutical company · small-cap · listed on Nasdaq · headquartered in Pennsylvania.
2
The Numbers
Annual revenue in the low hundreds of millions of dollars, with a portfolio built around a single core therapeutic area — a high-risk, high-focus strategy.
3
The History
Founded in 2017 and went public in 2020, making it one of the younger publicly traded pharma companies — barely old enough to vote, already selling prescription drugs.
4
The Secret
The entire business is laser-focused on sleep and wake disorders — conditions that affect tens of millions of Americans but have historically been underserved by drug development.
5
The Lore
Its flagship drug targets excessive daytime sleepiness associated with narcolepsy, competing in a niche where patients have long had few good options — and the company bet everything on it.
6
The Giveaway
The name itself promises peaceful rest: a neuroscience-focused pharma company whose lead product Wakix (pitolisant) was the first narcolepsy treatment with a novel mechanism approved in decades.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving HRMY's Business? Latest 10-Q Breakdown

AI-extracted from Harmony Biosciences Holdings, Inc.'s 10-Q filed 2026-08-04 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Net product revenue from sole product WAKIX rose 30.3% YoY to $261.3M on 26.5% unit growth plus a 7% price increase, lifting net income to $75.4M from $39.8M.

Biggest Revenue Drivers

Rare neurological diseases (WAKIX net product revenue)$261.3M+30.3% YoY

Sole reportable segment; all revenue derived from sales of WAKIX in the United States

Biggest Revenue Drivers

Total revenue: $261.3M+30.3% YoY

Rare neurological diseases (WAKIX net product revenue)$261.3M+30.3% YoY

Sole reportable segment; all revenue derived from sales of WAKIX in the United States

Within Rare neurological diseases (WAKIX net product revenue)

Units shipped+26.5% YoY

Average patients on WAKIX was approximately 8,950 for the three months ended June 30, 2026

Price+7%

January 2026 price increase, partially offset by higher rebates of approximately 4.0%

Largest Expense Items

Cost of product sold$63.2M+65.6% YoY

Higher royalties on increased WAKIX net revenue, plus new royalties under the Novitium License Agreement

Research and development$46.6M-7.1% YoY

Prior-year $15.0M CiRC IPR&D charge and ZYN002 phase-out, offset by $16.4M more spend on BP-205, EPX-100, Pitolisant GR/HD

Sales and marketing$34.1M+13.5% YoY

$2.0M more patient engagement and marketing and $1.6M higher personnel costs from sales force expansion

General and administrative$28.1M-17.3% YoY

$5.1M lower legal and professional fees after prior-year ANDA settlements and $2.4M less stock compensation

Margins: Cost of product sold rose to 24.2% of net product revenue from 19.0% a year ago, driven by new Novitium royalties; gross profit was $198.1M and operating income $89.3M.

Watch Items from the Filing

Three specialty pharmacies were 100% of gross product revenue for the six months: CVS Caremark 38%, Accredo 37%, Pantherx 25%; same three are 100% of receivables.
Generic settlements license WAKIX generics from July 2030 (Hikma March 2030) if pediatric exclusivity is granted; consolidated ANDA bench trial concluded February 19, 2026, oral arguments October 22, 2026.
Single commercialized product WAKIX, dependent on two API suppliers; supply covers demand into Q4 2028 with API for at least 24 months beyond.
$962.5M cash and investments against $155.0M debt; a nonfinancial covenant event of default dating to July 2025 was waived May 4, 2026.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$261.3M

Net Income

Q2 2026

$75.4M

ROIC

Q2 2026

30.4%

D/E Ratio

Q2 2026

0.17

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+21.5% YoY

$868.5MFY 2025

FY22 $437.9MFY23 $582.0MFY24 $714.7MFY25 $868.5M

Net Income

+9.1% YoY

$158.7MFY 2025

FY22 $181.5MFY23 $128.9MFY24 $145.5MFY25 $158.7M

Operating Income

+9.2% YoY

$208.5MFY 2025

FY22 $120.2MFY23 $192.0MFY24 $190.8MFY25 $208.5M

EPS (Diluted)

+8.0% YoY

$2.71FY 2025

FY22 $2.97FY23 $2.13FY24 $2.51FY25 $2.71

Total Assets

+27.3% YoY

$1.27BFY 2025

FY22 $673.9MFY23 $811.4MFY24 $999.2MFY25 $1.27B

Total Debt

-6.1% YoY

$183.7MFY 2025

FY22 $193.6MFY23 $208.6MFY24 $195.5MFY25 $183.7M

Op. Cash Flow

+58.4% YoY

$348.2MFY 2025

FY22 $144.5MFY23 $219.4MFY24 $219.8MFY25 $348.2M

Free Cash Flow

+59.1% YoY

$347.9MFY 2025

FY22 $144.3MFY23 $219.1MFY24 $218.7MFY25 $347.9M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$868.5M +21.5%	$714.7M +22.8%	$582.0M +32.9%	$437.9M +43.4%	$305.4M +91.2%	$159.7M
Net Income	$158.7M +9.1%	$145.5M +12.9%	$128.9M -29.0%	$181.5M +424.5%	$34.6M +193.6%	$-36.9M
Operating Income	$208.5M +9.2%	$190.8M -0.6%	$192.0M +59.8%	$120.2M +37.3%	$87.5M +415.3%	$17.0M
EPS (Diluted)	$2.71 +8.0%	$2.51 +17.8%	$2.13 -28.3%	$2.97 +412.1%	$0.58 +123.4%	$-2.48
Total Assets	$1.27B +27.3%	$999.2M +23.1%	$811.4M +20.4%	$673.9M +55.5%	$433.4M +1.5%	$427.1M
Total Debt	$183.7M -6.1%	$195.5M -6.3%	$208.6M +7.7%	$193.6M -0.2%	$194.0M -0.1%	$194.3M
Operating Cash Flow	$348.2M +58.4%	$219.8M +0.2%	$219.4M +51.9%	$144.5M +46.6%	$98.6M +3401.7%	$-3.0M
Free Cash Flow	$347.9M +59.1%	$218.7M -0.2%	$219.1M +51.8%	$144.3M +46.9%	$98.3M +3389.6%	$-3.0M

Get alerted when HRMY's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Harmony Biosciences Holdings, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of HRMY

BlackRock, Inc.
$258.6M7,101,965 sh
FMR LLC
$130.1M3,574,115 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$104.9M2,880,489 sh
AMERICAN CENTURY COMPANIES INC
$92.5M2,539,512 sh
DIMENSIONAL FUND ADVISORS LP
$87.1M2,393,588 sh
VANGUARD CAPITAL MANAGEMENT LLC
$76.6M2,105,053 sh
LSV ASSET MANAGEMENT
$75.0M2,061,242 sh
STATE STREET CORP
$67.7M1,859,322 sh
ARMISTICE CAPITAL, LLC
$56.9M1,564,000 sh
GEODE CAPITAL MANAGEMENT, LLC
$52.5M1,442,649 sh

Fund	Value	Shares
BlackRock, Inc.	$258.6M	7,101,965
FMR LLC	$130.1M	3,574,115
VANGUARD PORTFOLIO MANAGEMENT LLC	$104.9M	2,880,489
AMERICAN CENTURY COMPANIES INC	$92.5M	2,539,512
DIMENSIONAL FUND ADVISORS LP	$87.1M	2,393,588
VANGUARD CAPITAL MANAGEMENT LLC	$76.6M	2,105,053
LSV ASSET MANAGEMENT	$75.0M	2,061,242
STATE STREET CORP	$67.7M	1,859,322
ARMISTICE CAPITAL, LLC	$56.9M	1,564,000
GEODE CAPITAL MANAGEMENT, LLC	$52.5M	1,442,649

Companies Similar to HRMY

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

INVA

Innoviva, Inc.

AI score

Similar quality profile · 29 shared holders

ROYCE & ASSOCIATES LP Edgestream Partners, L.P.Susquehanna Portfolio Strategies, LLC

ACAD

ACADIA PHARMACEUTICALS INC

AI score

Similar quality profile · 26 shared holders

Edgestream Partners, L.P.SPHERA FUNDS MANAGEMENT LTD.TFG Asset Management GP Ltd

HALO

HALOZYME THERAPEUTICS, INC.

AI score

Similar quality profile · 15 shared holders

LSV ASSET MANAGEMENT Bridgewater Associates, LP JACOBS LEVY EQUITY MANAGEMENT, INC

RIGL

RIGEL PHARMACEUTICALS INC

AI score

Similar quality profile · 15 shared holders

ARMISTICE CAPITAL, LLC LSV ASSET MANAGEMENT Brandywine Global Investment Management, LLC

ANIP

ANI PHARMACEUTICALS INC

AI score

Similar quality profile · 26 shared holders

Bridge City Capital, LLC MARTINGALE ASSET MANAGEMENT L P Susquehanna Portfolio Strategies, LLC

COLL

COLLEGIUM PHARMACEUTICAL, INC

AI score

Similar quality profile · 22 shared holders

LSV ASSET MANAGEMENT ROYCE & ASSOCIATES LP Brandywine Global Investment Management, LLC

ADMA

ADMA BIOLOGICS, INC.

AI score

Similar quality profile · 16 shared holders

Bridgewater Associates, LP Virtus Investment Advisers, LLC DIADEMA PARTNERS LP

TBPH

Theravance Biopharma, Inc.

AI score

Similar quality profile · 14 shared holders

Weiss Asset Management LP CWA Asset Management Group, LLC WEDGE CAPITAL MANAGEMENT L L P/NC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put HRMY on your watchlist

Track score changes the day Harmony Biosciences Holdings, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is HRMY a good stock to buy?

13F Pro's AI-powered analysis of Harmony Biosciences Holdings, Inc. (HRMY) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for HRMY are available on the HRMY stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. HRMY is classified as a mid company.

Which hedge funds own HRMY?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling HRMY. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Harmony Biosciences Holdings, Inc.'s investment landscape.